Researchers at the National Institutes of Health (NIH) have developed a breath test that measures how well patients with methylmalonic acidemia (MMA) respond to receiving liver or combined liver and kidney transplantation. Researchers also used the test to assess the severity of the disease in people and help determine if they would benefit from surgical or experimental genomic therapies that target the liver.
The study results were published in Genetics in Medicine. Scientists at the National Human Genome Research Institute (NHGRI) led the project team, with collaborators from the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of Mental Health.
MMA is a rare genomic disease that impairs the body's ability to metabolize certain proteins and fats. This causes toxic substances to build up, which may result in kidney disease, pancreatitis, movement disorders, intellectual impairments, complications in many organs, and, in severe cases, death. One in 80,000 children born in the United States are diagnosed with MMA during newborn screenings. Currently, MMA is incurable, but people with MMA manage their symptoms through dietary restrictions and vitamin supplements. In extreme cases, patients receive liver or combined liver and kidney transplants, which help restore normal levels of metabolic proteins.
One form of MMA is caused by mutations in the methylmalonyl-CoA mutase gene (MMUT), which encodes for the MMUT protein. People with this form of MMA have a deficiency in the MMUT protein, which plays a pivotal part in metabolism. The protein is involved in the biological steps that help break down food, fats, cholesterol and amino acids.
MMUT helps break down food into a chemical byproduct called propionate, which is followed by an integral process involved in metabolism called oxidation. Through oxidation, a healthy body converts propionate into energy and carbon dioxide, which is exhaled, but that process is faulty for people with MMA.
Because MMUT protein function is compromised in people with MMA, the researchers chose to assess how well the MMUT protein helped break down propionate in both patients who did and not did not receive treatment. The researchers believed this would act as a proxy for how much oxidation was happening in a patient's body.
To detect if the MMUT protein was functioning properly, researchers gave patients a dose of the heavier, less abundant version of carbon – carbon 13 – via a commercially available food additive.
The team recruited 57 study participants, including 19 MMA patients who had received transplants (liver, kidney or both) and 16 healthy volunteers. Researchers gave participants a dose of the food additive containing carbon 13 via a drink or through a feeding tube, and then collected their breath samples after a two-minute wait.
The researchers measured how much of the exhaled carbon dioxide contained the usual carbon 12 compared to added carbon 13. As hypothesized, MMA patients who did not receive any treatment had lower levels of carbon 13 than healthy volunteers. By contrast, MMA patients with liver transplants had higher levels of carbon 13, similar to the healthy volunteers. This result indicated that the MMUT protein was helping oxidize the carbon 13 molecules by bonding with inhaled oxygen molecules.
Higher levels of carbon 13 oxidation also correlated with better clinical outcomes, such as improved cognition and slower decline in kidney function.
Currently, the test is only available for use at the NIH Clinical Center; however, the researchers hope it will soon be broadly adopted for clinical and research use.
